ARTICLE

Volume 11,Issue 2

Cite this article
16
Citations
37
Views
26 February 2026

Effect of Sacubitril-valsartan Combined with Metoprolol in the Treatment of Refractory Heart Failure in the Elderly

Yuyan Zhou*
Show Less
1 Wangzhuang Street Community Health Service Center, Wuxi 214000, Jiangsu, China
APM 2026 , 11(2), 58–63; https://doi.org/10.18063/APM.v11i2.1391
© 2026 by the Author. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Objective: To explore the effect of sacubitril-valsartan combined with metoprolol in the treatment of refractory heart failure in the elderly. Methods: 72 elderly patients with refractory heart failure were selected for data analysis in the outpatient clinic of our hospital from January 2024 to October 2025. They were divided into groups using the random number table method, with 36 patients in each group. The research group was treated with sacubitril-valsartan combined with metoprolol, and the control group was treated with metoprolol. The data between the groups were compared. Results: Compared with the control group, the total effective rate of the study group was significantly higher, the NT-proBNP index was significantly lower after treatment, and the inflammatory factors were significantly lower after treatment, p < 0.05; the NT-proBNP index and inflammatory factors before treatment were compared between the two groups, and the incidence of adverse reactions between the two groups was compared, p > 0.05. Conclusion: The effect of sacubitril-valsartan combined with metoprolol in the treatment of refractory heart failure in the elderly is ideal.

Keywords
Sacubitril-valsartan
Metoprolol
Elderly
Refractory heart failure
Effect
References

[1] Li Y, Li H, Cao R, et al., 2025, Effect of Sacubitril-Valsartan Combined with Metoprolol in the Treatment of Refractory Heart Failure in the Elderly. Chinese Journal of Drug Abuse Prevention, 31(2): 311–314.

[2] Zhang L, Li H, Han Y, 2024, Efficacy of Sacubitril-Valsartan Combined with Dapagliflozin in the Treatment of Elderly Patients with Chronic Heart Failure. Chinese Pharmacoeconomics, 19(12): 93–95 + 103.

[3] Liu L, Li Y, Zhao W, et al., 2024, Effect of Sacubitril-Valsartan in the Treatment of Heart Failure with Intermediate Ejection Fraction in the Elderly. Gerontology Research, 5(5): 7–11.

[4] Zhao J, 2024, Effect of Sacubitril-Valsartan Combined with Recombinant Human Brain Natriuretic Peptide in the Treatment of Refractory Heart Failure and Its Impact on Cardiac Function and NT-proBNP. Clinical Rational Drug Use, 17(24): 45–48.

[5] Yang J, Sun H, 2024, Efficacy of Sacubitril-Valsartan in the Treatment of Refractory Heart Failure and Its Impact on Cardiac Function. Clinical Rational Drug Use, 17(15): 57–60.

[6] Ni F, 2024, Clinical Effect of Sacubitril-Valsartan Combined with Milrinone in the Treatment of Refractory Heart Failure. Practical Clinical Integration of Traditional Chinese and Western Medicine, 24(4): 102–105.

[7] Li Z, Yang M, Zhou Z, et al., 2024, Clinical Effect of Levosimendan Combined with Sacubitril-Valsartan in the Treatment of Refractory Heart Failure. Jilin Medicine, 45(2): 398–400.

[8] Ding H, Liu Z, Liu M, 2023, Recombinant Human Brain Natriuretic Peptide Combined with Sacubitril-Valsartan in the Treatment of Refractory Heart Failure and Its Impact on Cardiac Function. Clinical Rational Drug Use, 16(3): 8–11.

Share
Back to top